Physician profile
Glenn A Davis
NPI 1932277654
$30,561.93
in general payments reported to CMS, 2019-2025
50 companies · $4,368 in 2025
The $4,368 reported for 2025 was more than what 97% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,120 · 2020: $3,227 · 2021: $4,767 · 2022: $4,375 · 2023: $4,952 · 2024: $3,752 · 2025: $4,368.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13,072.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $5,792.22 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $3,794.34 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Glaxosmithkline, LLC. | $2,430.58 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,820.69 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Novo Nordisk INC | $1,691.45 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $1,305.81 | 2019-2025 | |
| Lilly USA, LLC | $1,280.72 | 2019-2025 | Jardiance, Mounjaro, Emgality |
| Genzyme Corporation | $1,268.58 | 2019-2025 | |
| Amarin Pharma, INC. | $1,246.97 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $1,089.96 | 2019-2024 | Xarelto, Spravato |
| Amgen INC. | $949.19 | 2019-2025 | Tepezza, Repatha, Otezla |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $597.70 | 2019-2024 | Xifaxan |
| Allergan, INC. | $585.98 | 2019-2020 | |
| Exact Sciences Corporation | $584.46 | 2023-2025 | Cologuard Collection Kit |
| Sumitomo Pharma America, INC. | $529.19 | 2023-2025 | Gemtesa |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Glenn Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.